111 related articles for article (PubMed ID: 33634261)
1. A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis.
Geramizadeh B; Kohandel-Shirazi M; Soltani A
Clin Pathol; 2021; 14():2632010X20986168. PubMed ID: 33634261
[TBL] [Abstract][Full Text] [Related]
2. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
Camelo-Piragua S; Jansen M; Ganguly A; Kim JC; Cosper AK; Dias-Santagata D; Nutt CL; Iafrate AJ; Louis DN
J Neuropathol Exp Neurol; 2011 Feb; 70(2):110-5. PubMed ID: 21343879
[TBL] [Abstract][Full Text] [Related]
3. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Sipayya V; Sharma I; Sharma KC; Singh A
J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
[TBL] [Abstract][Full Text] [Related]
5.
Chatterjee D; Radotra BD; Kumar N; Vasishta RK; Gupta SK
Surg Neurol Int; 2018; 9():29. PubMed ID: 29527387
[TBL] [Abstract][Full Text] [Related]
6. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
[TBL] [Abstract][Full Text] [Related]
7. The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis.
Kaya Terzi N; Yılmaz İ; Öz AB
Balkan Med J; 2019 Jul; 36(4):222-228. PubMed ID: 30592195
[TBL] [Abstract][Full Text] [Related]
8. [Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
PIAO YS; LU DH; ZHANG XJ; TANG GC; YANG H
Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):156-60. PubMed ID: 21575384
[TBL] [Abstract][Full Text] [Related]
9. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
[TBL] [Abstract][Full Text] [Related]
10. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
[TBL] [Abstract][Full Text] [Related]
11. Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report.
Søndergaard CB; Scheie D; Sehested AM; Skjøth-Rasmussen J
Childs Nerv Syst; 2017 Jul; 33(7):1217-1220. PubMed ID: 28236063
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
13. EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.
Burel-Vandenbos F; Benchetrit M; Miquel C; Fontaine D; Auvergne R; Lebrun-Frenay C; Cardot-Leccia N; Michiels JF; Paquis-Flucklinger V; Virolle T
J Neurooncol; 2011 Apr; 102(2):171-8. PubMed ID: 20652725
[TBL] [Abstract][Full Text] [Related]
14. J1-31 protein expression in astrocytes and astrocytomas.
Shuangshoti S; Thorner PS; Ruangvejvorachai P; Saha B; Groshen S; Taylor CR; Malhotra S; Imam SA
Neuropathology; 2009 Oct; 29(5):521-7. PubMed ID: 19019178
[TBL] [Abstract][Full Text] [Related]
15. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis.
Camelo-Piragua S; Jansen M; Ganguly A; Kim JC; Louis DN; Nutt CL
Acta Neuropathol; 2010 Apr; 119(4):509-11. PubMed ID: 20044756
[No Abstract] [Full Text] [Related]
16. Differentiation between reactive gliosis and diffuse astrocytoma by in situ hybridization.
Wessels PH; Hopman AH; Ummelen MI; Krijne-Kubat B; Ramaekers FC; Twijnstra A
Neurology; 2001 May; 56(9):1224-7. PubMed ID: 11342694
[TBL] [Abstract][Full Text] [Related]
17. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Ishizawa K; Hirose T; Sugiyama K; Kageji T; Nobusawa S; Homma T; Komori T; Sasaki A
Clin Neuropathol; 2012; 31(2):67-76. PubMed ID: 22385787
[TBL] [Abstract][Full Text] [Related]
18. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
Suren D; Isiksacan Ozen O
J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
[TBL] [Abstract][Full Text] [Related]
19. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions.
Yaziji H; Massarani-Wafai R; Gujrati M; Kuhns JG; Martin AW; Parker JC
Am J Surg Pathol; 1996 Sep; 20(9):1086-90. PubMed ID: 8764745
[TBL] [Abstract][Full Text] [Related]
20. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
